Akums Drugs shares dropped more than 2% in morning trade on poor Q3 results. As of 10:11 AM, the shares were trading 2.25% lower at Rs 561.45.
The company reported a 6.7% drop in revenue, amounting to Rs 1,010 crore compared to Rs 1,083 crore in the previous fiscal year. Despite this setback, Akums saw a notable increase in EBITDA, which rose by 29.9% to Rs 121 crore, up from Rs 93.4 crore in Q3FY24. This improvement in EBITDA contributed to an enhanced EBITDA margin of 12%, up from 8.6% in the previous year.
However, the company’s net profit faced a sharp decline of 66.4%, falling to Rs 65.1 crore from Rs 194 crore in the corresponding quarter of the previous fiscal year. The dramatic drop in net profit reflects the pressure faced by Akums in managing its expenses and operational costs, despite the growth in EBITDA.
Akums Drugs’ shares opened today at ₹570.00, with the price reaching a high of ₹576.80 and a low of ₹555.05 during the session. The stock’s 52-week high stands at ₹1,175.90, while the 52-week low is ₹526.55.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
